<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377399</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA-A18-118042390157-9</org_study_id>
    <nct_id>NCT04377399</nct_id>
  </id_info>
  <brief_title>High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy</brief_title>
  <official_title>High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tameside Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim. To assess the effect of different doses of vitamin D supplementation on peripheral&#xD;
      neuropathy in patients with type 2 diabetes mellitus (T2DM).&#xD;
&#xD;
      68 patients with T2DM and peripheral neuropathy will be randomized into two treatment groups:&#xD;
      cholecalciferol 5,000 IU once/week and cholecalciferol 40,000 IU once/week orally for 24&#xD;
      weeks. Severity of neuropathy (neuropathy symptom score (NSS), neuropathy disability score&#xD;
      (NDS), visual analog scale (VAS)), body mass index (BMI), glycated hemoglobin (HbA1c),&#xD;
      25-hydroxycalciferol (25(OH)D), parathyroid hormone (PTH), serum interleukins (IL) 1β, 6 and&#xD;
      10, C-reactive protein, tumor necrosis factor α and microcirculation (MC) parameters assessed&#xD;
      before and after treatment. The initial and final indicators of the skin blood flow (M, σ,&#xD;
      Kv) and MC parameters after postural and occlusal tests by laser Doppler flowmetry (LDF).&#xD;
      Sixteen subjects without diabetes will represent the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that vitamin D deficiency along with type 2 diabetes mellitus (T2DM) is a&#xD;
      modern pandemic. Development of microvascular complications in T2DM worsens both the&#xD;
      prognosis and the patients' quality of life. There is increasing evidence of a possible&#xD;
      contribution of vitamin D deficiency to the pathogenesis of diabetes and its complications.&#xD;
      Large-scale studies have shown 40% increased risk of developing diabetes in individuals with&#xD;
      a reduced 25(OH)D level. A recent interventional prospective study demonstrated no decrease&#xD;
      in the risk of T2DM development in patients with prediabetes after two-year treatment with&#xD;
      4,000 IU of vitamin D per day. But, some experts suggested that 4,000 IU is not sufficient&#xD;
      supplementation dose for patients with already existing impaired glucose metabolism and on&#xD;
      the other hand most study participants had normal basal 25(OH)D level. Along with&#xD;
      immune-mediated mechanisms, microcirculation deterioration in patients with diabetes has been&#xD;
      found to play an important role in the pathogenesis of microvascular complications including&#xD;
      peripheral neuropathy (DPN).&#xD;
&#xD;
      It is believed that vitamin D deficiency also plays a role in the progression of DPN. Thus,&#xD;
      the correction of vitamin D deficiency in patients with T2DM is becoming increasingly&#xD;
      attractive for the prevention and treatment of microvascular complications. However, the&#xD;
      question of the required vitamin D dose and the treatment duration remain highly debatable.&#xD;
      The aim of this study was to assess the effect of therapy with different doses of&#xD;
      cholecalciferol for 24 weeks on clinical manifestations of peripheral neuropathy,&#xD;
      inflammatory markers, and parameters of microcirculation in patients with T2DM.&#xD;
&#xD;
      Patients and Methods: Baseline characteristics will be recorded for all patients including&#xD;
      Height, weight, BMI, diabetes status and biochemical parameters. All will be repeated at 24&#xD;
      weeks. Blood will be collected after an overnight fast and stored at -20 degrees until&#xD;
      analysis.&#xD;
&#xD;
      Patients will be recruited from the Almazov Research centre, St Petersburg, Russia&#xD;
      Federation.&#xD;
&#xD;
      68 patients with T2DM and peripheral neuropathy will be randomized into two treatment groups:&#xD;
      cholecalciferol 5,000 IU once/week and cholecalciferol 40,000 IU once/week orally for 24&#xD;
      weeks. Severity of neuropathy (neuropathy symptom score (NSS), neuropathy disability score&#xD;
      (NDS), visual analog scale (VAS)), body mass index (BMI), glycated hemoglobin (HbA1c),&#xD;
      25-hydroxycalciferol (25(OH)D), parathyroid hormone (PTH), serum interleukins (IL) 1β, 6 and&#xD;
      10, C-reactive protein, tumor necrosis factor α and microcirculation (MC) parameters assessed&#xD;
      before and after treatment. The initial and final indicators of the skin blood flow (M, σ,&#xD;
      Kv) and MC parameters after postural and occlusal tests by laser Doppler flowmetry (LDF).&#xD;
      Sixteen subjects without diabetes will represent the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">January 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Assessment of microcirculatory changes using laser doppler</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukins</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Serum interleukins (IL) will be determined by enzyme-linked immunosorbent assay (Bio-Rad 680 Microplate Reader, USA) using the appropriate sets of reagents for enzyme immunoassay to determine the concentration of IL-1β (reference values 0-5.0 pg/ml), IL-6 (reference values 0-7.0 pg/ml), IL-10 (reference values 0-9.1 pg/ml), (Vector-Best, Novosibirsk, Russia) compared from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor-α (TNFα)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Tumor necrosis factor-α (TNFα) will be determined by enzyme-linked immunosorbent assay (Bio-Rad 680 Microplate Reader, USA) using the appropriate sets of reagents for enzyme immunoassay to determine the concentration of TNFα (reference values 0-8.21 pg/ml) (Vector-Best, Novosibirsk, Russia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy disability score</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Using standard scoring systems and questionnaires. Scoring is: Neuropathy disability score (0-10),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Patients will be asked to score pain on a visual analog scale 0-10 with 10 being the worst pain ever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic symptom score</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>This will be scored using standard questionnaire 0-9</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Diabetes Type 2</condition>
  <condition>Diabetic Neuropathies</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D (40,000 IU weekly) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D (5,000 IU weekly) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males and females with T2DM aged 18 to 65 years&#xD;
&#xD;
          -  diabetes duration ≥5 years,&#xD;
&#xD;
          -  HbA1c &lt;9%,&#xD;
&#xD;
          -  stable hypoglycemic,&#xD;
&#xD;
          -  hypotensive and hypolipidemic therapy&#xD;
&#xD;
          -  neurological deficit 4 points and more according to the neuropathy disability score&#xD;
             (NDS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with type 1 diabetes&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  glomerular filtration rate (GFR) &lt;45 ml/min/1.73 m2&#xD;
&#xD;
          -  current and former smokers&#xD;
&#xD;
          -  obliterating atherosclerosis&#xD;
&#xD;
          -  diabetic foot or Charcot osteoarthropathy&#xD;
&#xD;
          -  inflammatory joint diseases&#xD;
&#xD;
          -  oncological diseases&#xD;
&#xD;
          -  ongoing infectious diseases or in the preceding four weeks&#xD;
&#xD;
          -  alcohol and drug addiction&#xD;
&#xD;
          -  history of В12 deficiency&#xD;
&#xD;
          -  anemia or current therapy with vitamin B12&#xD;
&#xD;
          -  regular use of glucocorticoids&#xD;
&#xD;
          -  vitamin D supplements&#xD;
&#xD;
          -  anticoagulants&#xD;
&#xD;
          -  antidepressants&#xD;
&#xD;
          -  tricyclic antidepressants&#xD;
&#xD;
          -  anticonvulsants&#xD;
&#xD;
          -  opiates&#xD;
&#xD;
          -  non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  vasoprotective and microcirculation correctors&#xD;
&#xD;
          -  alpha lipoic acid&#xD;
&#xD;
          -  group B vitamins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatiana Karonova, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Almazov National Medical Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

